blcm-20200619
0001358403falseNasdaq00013584032020-06-192020-06-19

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): June 19, 2020
Bellicum Pharmaceuticals, Inc.
(Exact name of registrant as specified in its charter)

Delaware001-3678320-1450200
(State or other jurisdiction
of incorporation)
(Commission
File Number)
(IRS Employer
Identification No.)
2130 W. Holcombe Blvd., Ste. 800, Houston, TX 77030
(Address of principal executive offices, including zip code)
Registrant’s telephone number, including area code: 832-384-1100
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:
 
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Common Stock, par value $0.01 per shareBLCM
The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). 
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.




Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On June 19, 2020, Alan K. Smith, Ph.D. notified Bellicum Pharmaceuticals, Inc. (the “Company”) of his resignation from his position as the Company’s Executive Vice President, Technical Operations, to be effective June 24, 2020.





SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Bellicum Pharmaceuticals, Inc.
Dated: June 23, 2020
By:
/s/ Richard A. Fair
Richard A. Fair
President and Chief Executive Officer





v3.20.1
Cover
Jun. 19, 2020
Cover [Abstract]  
Document Type 8-K
Document Period End Date Jun. 19, 2020
Entity Registrant Name Bellicum Pharmaceuticals, Inc.
Entity Incorporation, State or Country Code DE
Entity File Number 001-36783
Entity Tax Identification Number 20-1450200
Entity Address, Address Line One 2130 W. Holcombe Blvd.
Entity Address, Address Line Two Ste. 800
Entity Address, City or Town Houston
Entity Address, State or Province TX
Entity Address, Postal Zip Code 77030
City Area Code 832
Local Phone Number 384-1100
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, par value $0.01 per share
Trading Symbol BLCM
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
Entity Central Index Key 0001358403
Amendment Flag false